Quality of life of patients with gastrointestinal cancers undergoing chemotherapy

Ilufredo Y. Tantoy, Bruce A. Cooper, Anand Dhruva, Janine Cataldo, Steven M. Paul, Yvette P. Conley, Marilyn Hammer, Kord M. Kober, Jon D. Levine, Christine Miaskowski

Research output: Contribution to journalArticle

Abstract

Purpose: Findings regarding changes in the quality of life (QOL) of patients with gastrointestinal cancers (GI) undergoing chemotherapy (CTX) are inconclusive. Purpose was to evaluate for changes in QOL scores of patients with GI cancers over two cycles of CTX. Methods: Patients (n = 397) completed disease-specific [i.e., Quality of Life-Scale-Patient Version (QOL-PV)] and generic [12-item Medical Outcomes Study Short Form Survey (SF-12)] measures of QOL a total of six times over two cycles of CTX. Changes in these QOL scores were evaluated using bootstrapped multilevel regression with full information maximum likelihood estimation. Treatment group (i.e., with or without targeted therapy), age, number of metastatic sites, time from cancer diagnosis, number of prior cancer treatments, GI cancer diagnosis (i.e., colon/rectum/anal vs. other), and CTX regimen were evaluated as covariates in the conditional models for each of the QOL scores. Results: During the second cycle of CTX, QOL-PV scores decreased in the week following CTX administration, and then increased the following week. For both cycles of CTX, the physical component summary and mental component summary scores of the SF-12 decreased in the week following CTX administration and then increased the following week. Increased time from cancer diagnosis and a higher number of prior cancer treatments resulted in worse QOL-PV and SF-12 scores at enrollment. Conclusions: While changes in QOL scores over the two CTX cycles were statistically significant, the differences were not clinically meaningful. Future studies need to determine the optimal timing of QOL assessments to assess changes associated with cancer treatments.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalQuality of Life Research
DOIs
StateAccepted/In press - Apr 21 2018

Fingerprint

Gastrointestinal Neoplasms
Quality of Life
Drug Therapy
Neoplasms
Second Primary Neoplasms
Therapeutics
Rectum
Colon
Outcome Assessment (Health Care)

Keywords

  • Chemotherapy
  • Gastrointestinal cancer
  • Quality of life
  • Targeted therapy

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Tantoy, I. Y., Cooper, B. A., Dhruva, A., Cataldo, J., Paul, S. M., Conley, Y. P., ... Miaskowski, C. (Accepted/In press). Quality of life of patients with gastrointestinal cancers undergoing chemotherapy. Quality of Life Research, 1-12. https://doi.org/10.1007/s11136-018-1860-1

Quality of life of patients with gastrointestinal cancers undergoing chemotherapy. / Tantoy, Ilufredo Y.; Cooper, Bruce A.; Dhruva, Anand; Cataldo, Janine; Paul, Steven M.; Conley, Yvette P.; Hammer, Marilyn; Kober, Kord M.; Levine, Jon D.; Miaskowski, Christine.

In: Quality of Life Research, 21.04.2018, p. 1-12.

Research output: Contribution to journalArticle

Tantoy, IY, Cooper, BA, Dhruva, A, Cataldo, J, Paul, SM, Conley, YP, Hammer, M, Kober, KM, Levine, JD & Miaskowski, C 2018, 'Quality of life of patients with gastrointestinal cancers undergoing chemotherapy', Quality of Life Research, pp. 1-12. https://doi.org/10.1007/s11136-018-1860-1
Tantoy, Ilufredo Y. ; Cooper, Bruce A. ; Dhruva, Anand ; Cataldo, Janine ; Paul, Steven M. ; Conley, Yvette P. ; Hammer, Marilyn ; Kober, Kord M. ; Levine, Jon D. ; Miaskowski, Christine. / Quality of life of patients with gastrointestinal cancers undergoing chemotherapy. In: Quality of Life Research. 2018 ; pp. 1-12.
@article{b72d603b74e3498ea590f52c8557096c,
title = "Quality of life of patients with gastrointestinal cancers undergoing chemotherapy",
abstract = "Purpose: Findings regarding changes in the quality of life (QOL) of patients with gastrointestinal cancers (GI) undergoing chemotherapy (CTX) are inconclusive. Purpose was to evaluate for changes in QOL scores of patients with GI cancers over two cycles of CTX. Methods: Patients (n = 397) completed disease-specific [i.e., Quality of Life-Scale-Patient Version (QOL-PV)] and generic [12-item Medical Outcomes Study Short Form Survey (SF-12)] measures of QOL a total of six times over two cycles of CTX. Changes in these QOL scores were evaluated using bootstrapped multilevel regression with full information maximum likelihood estimation. Treatment group (i.e., with or without targeted therapy), age, number of metastatic sites, time from cancer diagnosis, number of prior cancer treatments, GI cancer diagnosis (i.e., colon/rectum/anal vs. other), and CTX regimen were evaluated as covariates in the conditional models for each of the QOL scores. Results: During the second cycle of CTX, QOL-PV scores decreased in the week following CTX administration, and then increased the following week. For both cycles of CTX, the physical component summary and mental component summary scores of the SF-12 decreased in the week following CTX administration and then increased the following week. Increased time from cancer diagnosis and a higher number of prior cancer treatments resulted in worse QOL-PV and SF-12 scores at enrollment. Conclusions: While changes in QOL scores over the two CTX cycles were statistically significant, the differences were not clinically meaningful. Future studies need to determine the optimal timing of QOL assessments to assess changes associated with cancer treatments.",
keywords = "Chemotherapy, Gastrointestinal cancer, Quality of life, Targeted therapy",
author = "Tantoy, {Ilufredo Y.} and Cooper, {Bruce A.} and Anand Dhruva and Janine Cataldo and Paul, {Steven M.} and Conley, {Yvette P.} and Marilyn Hammer and Kober, {Kord M.} and Levine, {Jon D.} and Christine Miaskowski",
year = "2018",
month = "4",
day = "21",
doi = "10.1007/s11136-018-1860-1",
language = "English (US)",
pages = "1--12",
journal = "Quality of Life Research",
issn = "0962-9343",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Quality of life of patients with gastrointestinal cancers undergoing chemotherapy

AU - Tantoy, Ilufredo Y.

AU - Cooper, Bruce A.

AU - Dhruva, Anand

AU - Cataldo, Janine

AU - Paul, Steven M.

AU - Conley, Yvette P.

AU - Hammer, Marilyn

AU - Kober, Kord M.

AU - Levine, Jon D.

AU - Miaskowski, Christine

PY - 2018/4/21

Y1 - 2018/4/21

N2 - Purpose: Findings regarding changes in the quality of life (QOL) of patients with gastrointestinal cancers (GI) undergoing chemotherapy (CTX) are inconclusive. Purpose was to evaluate for changes in QOL scores of patients with GI cancers over two cycles of CTX. Methods: Patients (n = 397) completed disease-specific [i.e., Quality of Life-Scale-Patient Version (QOL-PV)] and generic [12-item Medical Outcomes Study Short Form Survey (SF-12)] measures of QOL a total of six times over two cycles of CTX. Changes in these QOL scores were evaluated using bootstrapped multilevel regression with full information maximum likelihood estimation. Treatment group (i.e., with or without targeted therapy), age, number of metastatic sites, time from cancer diagnosis, number of prior cancer treatments, GI cancer diagnosis (i.e., colon/rectum/anal vs. other), and CTX regimen were evaluated as covariates in the conditional models for each of the QOL scores. Results: During the second cycle of CTX, QOL-PV scores decreased in the week following CTX administration, and then increased the following week. For both cycles of CTX, the physical component summary and mental component summary scores of the SF-12 decreased in the week following CTX administration and then increased the following week. Increased time from cancer diagnosis and a higher number of prior cancer treatments resulted in worse QOL-PV and SF-12 scores at enrollment. Conclusions: While changes in QOL scores over the two CTX cycles were statistically significant, the differences were not clinically meaningful. Future studies need to determine the optimal timing of QOL assessments to assess changes associated with cancer treatments.

AB - Purpose: Findings regarding changes in the quality of life (QOL) of patients with gastrointestinal cancers (GI) undergoing chemotherapy (CTX) are inconclusive. Purpose was to evaluate for changes in QOL scores of patients with GI cancers over two cycles of CTX. Methods: Patients (n = 397) completed disease-specific [i.e., Quality of Life-Scale-Patient Version (QOL-PV)] and generic [12-item Medical Outcomes Study Short Form Survey (SF-12)] measures of QOL a total of six times over two cycles of CTX. Changes in these QOL scores were evaluated using bootstrapped multilevel regression with full information maximum likelihood estimation. Treatment group (i.e., with or without targeted therapy), age, number of metastatic sites, time from cancer diagnosis, number of prior cancer treatments, GI cancer diagnosis (i.e., colon/rectum/anal vs. other), and CTX regimen were evaluated as covariates in the conditional models for each of the QOL scores. Results: During the second cycle of CTX, QOL-PV scores decreased in the week following CTX administration, and then increased the following week. For both cycles of CTX, the physical component summary and mental component summary scores of the SF-12 decreased in the week following CTX administration and then increased the following week. Increased time from cancer diagnosis and a higher number of prior cancer treatments resulted in worse QOL-PV and SF-12 scores at enrollment. Conclusions: While changes in QOL scores over the two CTX cycles were statistically significant, the differences were not clinically meaningful. Future studies need to determine the optimal timing of QOL assessments to assess changes associated with cancer treatments.

KW - Chemotherapy

KW - Gastrointestinal cancer

KW - Quality of life

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85045765963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045765963&partnerID=8YFLogxK

U2 - 10.1007/s11136-018-1860-1

DO - 10.1007/s11136-018-1860-1

M3 - Article

C2 - 29679368

AN - SCOPUS:85045765963

SP - 1

EP - 12

JO - Quality of Life Research

JF - Quality of Life Research

SN - 0962-9343

ER -